Volume | 69,772 |
|
|||||
News | (1) | ||||||
Day High | 3.41 | Low High |
|||||
Day Low | 2.98 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Century Therapeutics Inc | IPSC | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
3.05 | 2.98 | 3.41 | 3.13 | 3.04 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
1,434 | 69,772 | $ 3.11 | $ 217,256 | - | 1.28 - 5.51 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
18:07:58 | 25 | $ 3.30 | USD |
Century Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
204.82M | 64.82M | - | 2.24M | -136.67M | -2.11 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Century Therapeutics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical IPSC Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 3.10 | 3.70 | 2.90 | 3.12 | 122,331 | 0.03 | 0.97% |
1 Month | 4.01 | 4.07 | 2.75 | 3.09 | 128,699 | -0.88 | -21.95% |
3 Months | 4.68 | 5.51 | 2.75 | 4.01 | 198,654 | -1.55 | -33.12% |
6 Months | 1.45 | 5.51 | 1.28 | 3.53 | 188,949 | 1.68 | 115.86% |
1 Year | 3.36 | 5.51 | 1.28 | 3.13 | 148,877 | -0.23 | -6.85% |
3 Years | 19.50 | 32.899 | 1.28 | 10.26 | 145,711 | -16.37 | -83.95% |
5 Years | 19.50 | 32.899 | 1.28 | 10.26 | 145,711 | -16.37 | -83.95% |
Century Therapeutics Description
Century Therapeutics Inc is a biotechnology company developing transformative allogeneic cell therapies to create products for the treatment of both solid tumor and hematological malignancies with a plays a central role in the production of blood cells in the bone marrow. It is assembling a portfolio of allogeneic iNK and iT cell therapy product candidates across solid tumor and hematological malignancies. |